Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b/2 Study of Tafasitamab, Tafasitamab Plus Lenalidomide, Tafasitamab Plus Parsaclisib, and Tafasitamab Plus Lenalidomide in Combination With R-CHOP in Japanese Participants With Non-Hodgkin Lymphoma

NCT04661007 is registered in ClinicalTrials.gov with Incyte Biosciences Japan GK as lead sponsor.

NCT NCT04661007
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04661007 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b/2 Study of Tafasitamab, Tafasitamab Plus Lenalidomide, Tafasitamab Plus Parsaclisib, and Tafasitamab Plus Lenalidomide in Combination With R-CHOP in Japanese Participants With Non-Hodgkin Lymphoma
Lead sponsor
Incyte Biosciences Japan GK
Phase
Phase 1/2
Overall status
Active, not recruiting
Start date
December 15, 2020
Completion date
December 31, 2026
Enrollment
72 (actual)
Sites
23

Conditions

As the registry lists them; a condition with its own page is linked.

diffuse large b-cell lymphoma, non hodgkins lymphoma